Atossa Genetics (ATOS)
(Delayed Data from NSDQ)
$1.53 USD
+0.01 (0.66%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $1.52 -0.01 (-0.65%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth D Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ATOS 1.53 +0.01(0.66%)
Will ATOS be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ATOS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ATOS
Atossa (ATOS) Reports Positive Results From EVANGELINE Study
Is Atossa Genetics (ATOS) Outperforming Other Medical Stocks This Year?
ATOS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for ATOS
Promising Synergies: Atossa Therapeutics’ Advances in ER+/HER2- Breast Cancer Treatment
Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer
Atossa Therapeutics, Quantum Leap announces initiation of I-SPY 2 trial
Video: Friday 4/12 Insider Buying Report: ATOS, TRDA
Atossa to Participate in Noble Capital Markets Emerging Growth Healthcare Conference